Cesar Martin Castro, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Biosensing Techniques | 10 | 2024 | 662 | 1.220 |
Why?
|
Neoplastic Cells, Circulating | 7 | 2023 | 952 | 1.100 |
Why?
|
Magnetic Resonance Spectroscopy | 7 | 2018 | 3780 | 0.870 |
Why?
|
Ovarian Neoplasms | 14 | 2024 | 4915 | 0.840 |
Why?
|
Exosomes | 5 | 2017 | 422 | 0.780 |
Why?
|
Nanotechnology | 3 | 2017 | 714 | 0.730 |
Why?
|
Surface Plasmon Resonance | 3 | 2020 | 272 | 0.660 |
Why?
|
Holography | 2 | 2018 | 80 | 0.650 |
Why?
|
Point-of-Care Systems | 11 | 2023 | 1238 | 0.630 |
Why?
|
Magnetite Nanoparticles | 3 | 2017 | 312 | 0.600 |
Why?
|
Microfluidics | 4 | 2017 | 672 | 0.570 |
Why?
|
Early Detection of Cancer | 4 | 2024 | 3238 | 0.570 |
Why?
|
Cervix Uteri | 2 | 2024 | 577 | 0.550 |
Why?
|
Uterine Cervical Neoplasms | 4 | 2024 | 2043 | 0.530 |
Why?
|
Miniaturization | 2 | 2013 | 154 | 0.520 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2016 | 618 | 0.460 |
Why?
|
Staining and Labeling | 2 | 2022 | 1080 | 0.430 |
Why?
|
Nanoparticles | 8 | 2024 | 1983 | 0.430 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2016 | 1335 | 0.380 |
Why?
|
Lymphoma | 2 | 2016 | 1897 | 0.340 |
Why?
|
Flow Cytometry | 1 | 2020 | 5904 | 0.340 |
Why?
|
Microfluidic Analytical Techniques | 5 | 2017 | 820 | 0.330 |
Why?
|
Folate Receptor 1 | 3 | 2024 | 41 | 0.320 |
Why?
|
Endometrial Neoplasms | 3 | 2023 | 1382 | 0.320 |
Why?
|
Nanomedicine | 1 | 2011 | 292 | 0.310 |
Why?
|
Electrochemical Techniques | 2 | 2021 | 94 | 0.300 |
Why?
|
Nucleic Acids | 2 | 2023 | 189 | 0.290 |
Why?
|
Immunoconjugates | 3 | 2024 | 975 | 0.280 |
Why?
|
Neoplasms | 9 | 2023 | 22369 | 0.270 |
Why?
|
Indoles | 3 | 2021 | 1835 | 0.260 |
Why?
|
Maytansine | 2 | 2024 | 88 | 0.260 |
Why?
|
Carboplatin | 2 | 2024 | 791 | 0.220 |
Why?
|
Cystadenocarcinoma, Papillary | 1 | 2023 | 56 | 0.220 |
Why?
|
Gold | 2 | 2024 | 488 | 0.210 |
Why?
|
Neoplasms, Glandular and Epithelial | 2 | 2017 | 489 | 0.200 |
Why?
|
Membrane Proteins | 1 | 2019 | 7876 | 0.190 |
Why?
|
Silicon Dioxide | 2 | 2024 | 218 | 0.180 |
Why?
|
Uteroglobin | 1 | 2000 | 55 | 0.180 |
Why?
|
Biotinylation | 1 | 2020 | 185 | 0.170 |
Why?
|
Peritoneal Neoplasms | 2 | 2024 | 707 | 0.170 |
Why?
|
Biopsy, Fine-Needle | 4 | 2020 | 1134 | 0.170 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 11874 | 0.170 |
Why?
|
Breast Neoplasms | 6 | 2022 | 21209 | 0.160 |
Why?
|
Humans | 68 | 2024 | 767998 | 0.160 |
Why?
|
Neurosecretory Systems | 1 | 2000 | 223 | 0.160 |
Why?
|
Microspheres | 3 | 2017 | 788 | 0.160 |
Why?
|
Human papillomavirus 18 | 1 | 2019 | 125 | 0.160 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2023 | 480 | 0.160 |
Why?
|
Substance Abuse Detection | 1 | 2021 | 301 | 0.160 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2024 | 9412 | 0.150 |
Why?
|
Papillomavirus Infections | 2 | 2024 | 1640 | 0.150 |
Why?
|
Biological Assay | 2 | 2021 | 627 | 0.150 |
Why?
|
Human papillomavirus 16 | 1 | 2019 | 268 | 0.150 |
Why?
|
Papillomaviridae | 2 | 2024 | 1140 | 0.150 |
Why?
|
Food Safety | 1 | 2017 | 23 | 0.140 |
Why?
|
Neoplasm Proteins | 3 | 2014 | 3601 | 0.140 |
Why?
|
Cholangiocarcinoma | 1 | 2023 | 561 | 0.140 |
Why?
|
Bile Duct Neoplasms | 1 | 2023 | 614 | 0.140 |
Why?
|
Inorganic Chemicals | 1 | 2016 | 10 | 0.140 |
Why?
|
CA-19-9 Antigen | 1 | 2017 | 109 | 0.140 |
Why?
|
Dengue Virus | 1 | 2018 | 204 | 0.130 |
Why?
|
Sepsis | 2 | 2023 | 2608 | 0.130 |
Why?
|
Capsules | 1 | 2017 | 193 | 0.130 |
Why?
|
Cell Fractionation | 1 | 2017 | 247 | 0.130 |
Why?
|
Plastics | 1 | 2017 | 119 | 0.130 |
Why?
|
Filtration | 1 | 2017 | 229 | 0.130 |
Why?
|
Fluorescence Polarization | 1 | 2016 | 139 | 0.130 |
Why?
|
Influenza in Birds | 1 | 2016 | 76 | 0.130 |
Why?
|
Biomimetics | 1 | 2017 | 172 | 0.130 |
Why?
|
Cell Line, Tumor | 9 | 2019 | 17128 | 0.120 |
Why?
|
Computers, Handheld | 1 | 2017 | 211 | 0.120 |
Why?
|
Dengue | 1 | 2018 | 258 | 0.120 |
Why?
|
Ascites | 2 | 2015 | 338 | 0.120 |
Why?
|
Pancreatic Neoplasms | 3 | 2020 | 5447 | 0.120 |
Why?
|
Coated Materials, Biocompatible | 1 | 2017 | 311 | 0.120 |
Why?
|
Acute Kidney Injury | 2 | 2024 | 1946 | 0.110 |
Why?
|
Genes, BRCA2 | 1 | 2017 | 593 | 0.110 |
Why?
|
Proteins | 2 | 2017 | 6009 | 0.110 |
Why?
|
Antineoplastic Agents | 3 | 2023 | 13658 | 0.110 |
Why?
|
Female | 34 | 2024 | 397102 | 0.110 |
Why?
|
Cathepsin E | 1 | 2013 | 3 | 0.110 |
Why?
|
Bacteria | 2 | 2016 | 2216 | 0.110 |
Why?
|
Genes, BRCA1 | 1 | 2017 | 755 | 0.110 |
Why?
|
Cyclooctanes | 1 | 2013 | 37 | 0.110 |
Why?
|
Qualitative Research | 1 | 2024 | 3141 | 0.110 |
Why?
|
Lab-On-A-Chip Devices | 1 | 2017 | 445 | 0.110 |
Why?
|
Ribose | 2 | 2023 | 63 | 0.110 |
Why?
|
Image Processing, Computer-Assisted | 3 | 2018 | 9016 | 0.100 |
Why?
|
Catheter-Related Infections | 1 | 2016 | 275 | 0.100 |
Why?
|
Anti-Mullerian Hormone | 1 | 2015 | 420 | 0.100 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2015 | 719 | 0.100 |
Why?
|
Bacterial Typing Techniques | 1 | 2013 | 263 | 0.100 |
Why?
|
Influenza A virus | 1 | 2016 | 460 | 0.100 |
Why?
|
Protein Array Analysis | 1 | 2014 | 399 | 0.100 |
Why?
|
Cerebrospinal Fluid | 1 | 2015 | 540 | 0.100 |
Why?
|
Cell-Derived Microparticles | 1 | 2013 | 160 | 0.100 |
Why?
|
Luminescence | 2 | 2024 | 108 | 0.100 |
Why?
|
Ferric Compounds | 1 | 2013 | 376 | 0.100 |
Why?
|
Boron Compounds | 1 | 2013 | 196 | 0.090 |
Why?
|
Ritonavir | 1 | 2013 | 331 | 0.090 |
Why?
|
Protein Isoforms | 1 | 2016 | 1715 | 0.090 |
Why?
|
Factor XIII Deficiency | 1 | 2010 | 16 | 0.090 |
Why?
|
HIV Protease Inhibitors | 1 | 2013 | 430 | 0.090 |
Why?
|
Genital Neoplasms, Female | 1 | 2016 | 536 | 0.090 |
Why?
|
Dependovirus | 1 | 2015 | 720 | 0.090 |
Why?
|
Mammography | 1 | 2021 | 2433 | 0.080 |
Why?
|
Allergens | 1 | 2017 | 1436 | 0.080 |
Why?
|
Polymers | 1 | 2017 | 1627 | 0.080 |
Why?
|
Food Hypersensitivity | 1 | 2017 | 734 | 0.080 |
Why?
|
Germ-Line Mutation | 1 | 2017 | 1885 | 0.080 |
Why?
|
Viral Proteins | 1 | 2016 | 1802 | 0.080 |
Why?
|
Lung | 2 | 2013 | 10096 | 0.080 |
Why?
|
Antibodies | 2 | 2014 | 2421 | 0.080 |
Why?
|
High-Throughput Screening Assays | 1 | 2014 | 942 | 0.080 |
Why?
|
Sensitivity and Specificity | 4 | 2020 | 14718 | 0.080 |
Why?
|
Precancerous Conditions | 1 | 2015 | 984 | 0.070 |
Why?
|
Aged, 80 and over | 10 | 2024 | 59600 | 0.070 |
Why?
|
RNA | 1 | 2017 | 2718 | 0.070 |
Why?
|
DNA | 3 | 2023 | 7213 | 0.070 |
Why?
|
MicroRNAs | 1 | 2023 | 3804 | 0.070 |
Why?
|
Biopsy | 3 | 2013 | 6786 | 0.070 |
Why?
|
Cross Infection | 1 | 2016 | 1426 | 0.070 |
Why?
|
Area Under Curve | 2 | 2021 | 1642 | 0.070 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2015 | 3609 | 0.070 |
Why?
|
Hydrogels | 2 | 2023 | 744 | 0.070 |
Why?
|
Central Nervous System Neoplasms | 1 | 2015 | 928 | 0.070 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2017 | 1759 | 0.060 |
Why?
|
Middle Aged | 16 | 2024 | 223422 | 0.060 |
Why?
|
Paclitaxel | 2 | 2023 | 1728 | 0.060 |
Why?
|
Ligands | 2 | 2022 | 3284 | 0.060 |
Why?
|
Aged | 14 | 2024 | 171453 | 0.060 |
Why?
|
Fluorescent Dyes | 1 | 2013 | 1929 | 0.060 |
Why?
|
Erbium | 1 | 2024 | 13 | 0.060 |
Why?
|
Thulium | 1 | 2024 | 21 | 0.060 |
Why?
|
Lymph Nodes | 1 | 2016 | 3472 | 0.060 |
Why?
|
Algorithms | 3 | 2022 | 14163 | 0.060 |
Why?
|
Pathology, Molecular | 2 | 2018 | 328 | 0.060 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2022 | 2884 | 0.060 |
Why?
|
Erythrocytes | 1 | 2013 | 2418 | 0.060 |
Why?
|
Graft Rejection | 1 | 2017 | 4500 | 0.060 |
Why?
|
Adult | 15 | 2024 | 223577 | 0.060 |
Why?
|
Tissue Array Analysis | 2 | 2016 | 547 | 0.060 |
Why?
|
Plasma | 2 | 2022 | 584 | 0.060 |
Why?
|
Electroosmosis | 1 | 2023 | 8 | 0.060 |
Why?
|
Equipment Design | 3 | 2017 | 3522 | 0.050 |
Why?
|
Limit of Detection | 1 | 2024 | 277 | 0.050 |
Why?
|
Proteomics | 3 | 2023 | 3912 | 0.050 |
Why?
|
Luminescent Measurements | 1 | 2024 | 342 | 0.050 |
Why?
|
BRCA1 Protein | 2 | 2021 | 1155 | 0.050 |
Why?
|
Fallopian Tubes | 1 | 2023 | 179 | 0.050 |
Why?
|
Neoplasm Metastasis | 1 | 2013 | 4904 | 0.050 |
Why?
|
Diphosphates | 1 | 2022 | 89 | 0.050 |
Why?
|
Reproducibility of Results | 3 | 2015 | 20218 | 0.050 |
Why?
|
Radiography | 1 | 2013 | 6981 | 0.050 |
Why?
|
Antibodies, Immobilized | 1 | 2021 | 22 | 0.050 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2023 | 304 | 0.050 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2023 | 428 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2021 | 6973 | 0.050 |
Why?
|
Fallopian Tube Neoplasms | 1 | 2024 | 329 | 0.050 |
Why?
|
Time Factors | 3 | 2016 | 40210 | 0.040 |
Why?
|
Phthalazines | 1 | 2022 | 397 | 0.040 |
Why?
|
Platinum | 1 | 2021 | 222 | 0.040 |
Why?
|
Uganda | 1 | 2024 | 1361 | 0.040 |
Why?
|
DNA Mismatch Repair | 1 | 2022 | 431 | 0.040 |
Why?
|
Cerebral Hemorrhage | 1 | 2010 | 2655 | 0.040 |
Why?
|
Lipoproteins, LDL | 1 | 2022 | 644 | 0.040 |
Why?
|
Hyperplasia | 1 | 2022 | 1151 | 0.040 |
Why?
|
Spectrum Analysis, Raman | 1 | 2020 | 253 | 0.040 |
Why?
|
Patient Advocacy | 1 | 2001 | 362 | 0.040 |
Why?
|
Organoplatinum Compounds | 1 | 2020 | 406 | 0.040 |
Why?
|
Calcitonin Gene-Related Peptide | 1 | 2000 | 327 | 0.040 |
Why?
|
Inflammation | 1 | 2017 | 10872 | 0.040 |
Why?
|
Botswana | 1 | 2021 | 1058 | 0.040 |
Why?
|
DNA, Viral | 1 | 2024 | 2201 | 0.040 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2024 | 1488 | 0.030 |
Why?
|
Electronics | 1 | 2018 | 317 | 0.030 |
Why?
|
Saliva | 1 | 2021 | 853 | 0.030 |
Why?
|
Complementary Therapies | 1 | 2001 | 487 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2023 | 5335 | 0.030 |
Why?
|
Thrombocytopenia | 1 | 2024 | 1178 | 0.030 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2023 | 1656 | 0.030 |
Why?
|
Tropism | 1 | 2015 | 44 | 0.030 |
Why?
|
Antibodies, Monoclonal | 2 | 2023 | 9253 | 0.030 |
Why?
|
Birds | 1 | 2016 | 166 | 0.030 |
Why?
|
Drug Synergism | 1 | 2019 | 1760 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2021 | 10757 | 0.030 |
Why?
|
Hydrophobic and Hydrophilic Interactions | 1 | 2016 | 393 | 0.030 |
Why?
|
Kidney | 2 | 2023 | 7067 | 0.030 |
Why?
|
Tandem Mass Spectrometry | 1 | 2021 | 1197 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2023 | 3553 | 0.030 |
Why?
|
Social Support | 1 | 2024 | 2193 | 0.030 |
Why?
|
Recurrence | 2 | 2021 | 8507 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2022 | 2253 | 0.030 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2015 | 304 | 0.030 |
Why?
|
Physician's Role | 1 | 2001 | 925 | 0.030 |
Why?
|
Surface Properties | 1 | 2017 | 1165 | 0.030 |
Why?
|
Ascitic Fluid | 1 | 2014 | 189 | 0.030 |
Why?
|
Receptors, Peptide | 1 | 2015 | 280 | 0.030 |
Why?
|
Spheroids, Cellular | 1 | 2015 | 331 | 0.030 |
Why?
|
ROC Curve | 1 | 2021 | 3628 | 0.030 |
Why?
|
Metals | 1 | 2017 | 713 | 0.030 |
Why?
|
Click Chemistry | 1 | 2013 | 101 | 0.030 |
Why?
|
Drug Resistance, Microbial | 1 | 2016 | 830 | 0.030 |
Why?
|
Administration, Oral | 1 | 2021 | 4030 | 0.030 |
Why?
|
BRCA2 Protein | 1 | 2017 | 802 | 0.030 |
Why?
|
Inhibitory Concentration 50 | 1 | 2013 | 464 | 0.030 |
Why?
|
Erythrocyte Membrane | 1 | 2013 | 438 | 0.020 |
Why?
|
Alphapapillomavirus | 1 | 2015 | 219 | 0.020 |
Why?
|
Transgenes | 1 | 2015 | 1016 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2022 | 2601 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2019 | 4857 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 904 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2023 | 2903 | 0.020 |
Why?
|
Mice | 4 | 2023 | 82024 | 0.020 |
Why?
|
Male | 7 | 2024 | 364638 | 0.020 |
Why?
|
Thalamic Diseases | 1 | 2010 | 15 | 0.020 |
Why?
|
Alternative Splicing | 1 | 2016 | 1104 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2018 | 6119 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2021 | 6843 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 3814 | 0.020 |
Why?
|
Magnetics | 1 | 2013 | 597 | 0.020 |
Why?
|
Health Personnel | 1 | 2024 | 3387 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2021 | 6517 | 0.020 |
Why?
|
Muscles | 1 | 2015 | 1582 | 0.020 |
Why?
|
Attitude of Health Personnel | 1 | 2024 | 3930 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2024 | 3231 | 0.020 |
Why?
|
Exons | 1 | 2016 | 2393 | 0.020 |
Why?
|
Phospholipids | 1 | 2013 | 785 | 0.020 |
Why?
|
Blood Coagulation Tests | 1 | 2010 | 269 | 0.020 |
Why?
|
Reference Standards | 1 | 2013 | 1013 | 0.020 |
Why?
|
Tumor Burden | 1 | 2015 | 1904 | 0.020 |
Why?
|
Animals | 5 | 2023 | 169225 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2013 | 13500 | 0.020 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2013 | 1049 | 0.020 |
Why?
|
International Normalized Ratio | 1 | 2010 | 382 | 0.020 |
Why?
|
Species Specificity | 1 | 2013 | 2414 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2015 | 10471 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2000 | 3703 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2023 | 11221 | 0.020 |
Why?
|
Neoplastic Stem Cells | 1 | 2016 | 1351 | 0.020 |
Why?
|
Prognosis | 2 | 2021 | 29984 | 0.020 |
Why?
|
Image Enhancement | 1 | 2018 | 2880 | 0.020 |
Why?
|
Cytokines | 1 | 2023 | 7453 | 0.020 |
Why?
|
Hemoglobins | 1 | 2013 | 1531 | 0.020 |
Why?
|
Mucin-1 | 1 | 2012 | 536 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2022 | 2666 | 0.020 |
Why?
|
Survival Analysis | 1 | 2019 | 10096 | 0.020 |
Why?
|
Blood Transfusion | 1 | 2013 | 1308 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2022 | 12797 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2024 | 5520 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2015 | 3740 | 0.020 |
Why?
|
Cell Separation | 1 | 2012 | 1729 | 0.020 |
Why?
|
Host-Pathogen Interactions | 1 | 2015 | 1469 | 0.020 |
Why?
|
Genotype | 1 | 2000 | 13042 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2013 | 2149 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2001 | 4529 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2000 | 14484 | 0.020 |
Why?
|
Cerebral Angiography | 1 | 2010 | 1264 | 0.020 |
Why?
|
United States | 3 | 2023 | 73033 | 0.010 |
Why?
|
Mass Screening | 1 | 2021 | 5458 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2021 | 14785 | 0.010 |
Why?
|
Nitric Oxide | 1 | 2013 | 2146 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 2016 | 3216 | 0.010 |
Why?
|
Software | 1 | 2018 | 4479 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2022 | 65360 | 0.010 |
Why?
|
Prospective Studies | 2 | 2020 | 54921 | 0.010 |
Why?
|
Magnetic Resonance Angiography | 1 | 2010 | 1429 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2023 | 81748 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2000 | 11666 | 0.010 |
Why?
|
Cell Line | 1 | 2017 | 15597 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2013 | 3140 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 2017 | 4271 | 0.010 |
Why?
|
Single-Cell Analysis | 1 | 2014 | 2543 | 0.010 |
Why?
|
Base Sequence | 1 | 2013 | 12417 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 5536 | 0.010 |
Why?
|
Signal Transduction | 2 | 2015 | 23640 | 0.010 |
Why?
|
Young Adult | 2 | 2021 | 60050 | 0.010 |
Why?
|
Social Conditions | 1 | 2001 | 121 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2013 | 17617 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2016 | 8637 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2017 | 10264 | 0.010 |
Why?
|
Marketing of Health Services | 1 | 2001 | 151 | 0.010 |
Why?
|
Critical Care | 1 | 2010 | 2715 | 0.010 |
Why?
|
Telemedicine | 1 | 2015 | 3109 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2014 | 5694 | 0.010 |
Why?
|
Public Opinion | 1 | 2001 | 485 | 0.010 |
Why?
|
Phenotype | 1 | 2013 | 16723 | 0.010 |
Why?
|
Adolescent | 1 | 2021 | 89154 | 0.010 |
Why?
|
United States Food and Drug Administration | 1 | 2001 | 1671 | 0.010 |
Why?
|
Mutation | 1 | 2016 | 30214 | 0.010 |
Why?
|
Cohort Studies | 1 | 2013 | 41753 | 0.010 |
Why?
|
Medical Oncology | 1 | 2001 | 2341 | 0.000 |
Why?
|
Caregivers | 1 | 2001 | 2302 | 0.000 |
Why?
|
Patient Satisfaction | 1 | 2001 | 3488 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 2010 | 20757 | 0.000 |
Why?
|